GlassScriptPhysician profile
Rae A High
NPI 1487033072
$865.48
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $865.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $202.13 | 2021 | |
| Novo Nordisk INC | $119.18 | 2021 | |
| Glaxosmithkline, LLC. | $114.89 | 2021 | |
| Novartis Pharmaceuticals Corporation | $52.05 | 2021 | |
| Horizon Therapeutics Plc | $39.75 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $37.99 | 2021 | |
| Indivior INC. | $34.94 | 2021 | |
| Janssen Pharmaceuticals, INC | $33.57 | 2021 | |
| Dexcom, INC. | $33.20 | 2021 | |
| Pfizer INC. | $30.12 | 2021 | |
| Bard Peripheral Vascular, INC. | $30.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.57 | 2021 | |
| Abbott Laboratories | $19.68 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $18.41 | 2021 | |
| Abbvie INC. | $15.86 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $15.40 | 2021 | |
| Amgen INC. | $13.42 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.19 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.13 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rae High listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.